RESUMO
Depression is more common among people with chronic conditions than in the general population and can negatively influence both health behaviours and outcomes. The Chronic Disease Self-Management Programme (CDSMP) is a six-week psycho-educational programme designed to promote self-efficacy and to teach patients skills for managing their chronic conditions. A longitudinal design evaluated the effect of the CDSMP on depression in an Irish cohort. Self-report data on psychological wellbeing were collected at baseline (n = 263), immediately post-program (n = 102), and six months (n = 81) after enrolment. CDSMP participation was associated with a significant decrease in the mean depression score of the whole sample, across the three time points. Significant improvements in quality of life and health interference in social activities were also observed among those who met criteria for depression on the PHQ-8 at baseline, but not their peers with sub-threshold depression scores. Quality of life continued to improve between the end of the programme and 6-month follow-up. These findings support the efficacy of the CDSMP in the treatment of chronic conditions, as well as its role in promoting sustainable changes to quality of life.
Assuntos
Qualidade de Vida , Autogestão , Doença Crônica , Depressão/epidemiologia , Depressão/terapia , Humanos , AutocuidadoRESUMO
BACKGROUND: Consensus guidelines from the European Crohns and Colitis Organisation conclude that optimizing quality of care in inflammatory bowel disease [IBD] involves information and education. However, there is no standardized patient education programme in IBD and education varies from centre to centre. AIM: To assess patients' education needs in IBD to facilitate design of a patient education programme. METHODS: We created focus groups of 12 patients with IBD and used qualitative analysis to generate hypotheses. We then developed a quantitative questionnaire which was disseminated to 327 IBD patients attending three different centres. Five patients declined to participate and thus 322 patients (159 [49%] male, 180 [58%] Crohn's disease, median age 38 years and disease duration 7 years) were included. RESULTS: Patients were most keen to receive education on medications, 'what to expect in future', living with IBD and diet. They wanted to receive this information from specialist doctors or nurses and believed it could improve their quality of life. Though the internet was the preferred source of general information [i.e. planning holidays], it was the least preferred source of IBD education. While there was a trend for females to prefer peer education, family history of IBD was the only statistically significant factor associated with information preferences. CONCLUSION: This is a patient-centred, mixed methodology study on patient education in IBD. Patients' preferences for education include components such as what to expect and diet and patients seem to distrust the internet as an IBD information source. International validation would be valuable to create a consensus education programme.
Assuntos
Colite Ulcerativa , Doença de Crohn , Comportamento de Busca de Informação , Educação de Pacientes como Assunto , Adulto , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Dieta , Feminino , Grupos Focais , Fármacos Gastrointestinais/uso terapêutico , Humanos , Internet , Masculino , Pessoa de Meia-Idade , Avaliação das Necessidades , Preferência do Paciente , Qualidade de Vida , Inquéritos e QuestionáriosRESUMO
OBJECTIVE: The aim of this study was to assess attitudes towards and knowledge of medication safety in inflammatory bowel disease (IBD). IBD patients frequently require long-term treatment with potentially toxic medications. Techniques are employed to improve patient awareness of medication safety, but there are sparse data on their effectiveness. MATERIAL AND METHODS: Questionnaires relating to the safety and efficacy of commonly used IBD treatments (aminosalicylates, corticosteroids, immunomodulators, biologics) were completed by IBD patients attending the gastroenterology clinics at a teaching hospital. RESULTS: One hundred patients (51 male) with a median (interquartile range) age of 37 (29-49) years were included: 56 Crohn's disease, 44 ulcerative colitis. Aminosalicylates (median 0.8 (IQR 0.1-1.9)) were ranked as the safest medication; corticosteroids (4.6 (1.1-8.2)), immunomodulators (4.2 (1.1-8.4) and biologics (4.4 (1.1-6.8)) were ranked equally. 36%, 53% and 79% reported no knowledge regarding safety of corticosteroids, immunomodulators and biologics, respectively. Most patients wish to be informed of all medication side-effects, no matter how rare, and ranked their gastroenterologist as their primary information source. CONCLUSIONS: IBD patients want to be informed of all potential adverse events and identify their gastroenterologist as their principal information source. The majority have no knowledge regarding or underestimate the toxicity of common IBD medications. This places a responsibility on gastroenterologists to manage and meet patients' expectations in the area of medication safety.